1. On behalf of all principal COMPARE II investigators:
Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow -up data from COMPARE II study
Pieter Cornelis Smits
On behalf of all principal COMPARE II investigators:
A. J. van Boven, Mariano Valdes, Antonio Serra, Jean-Jacques Goy, V. Voudris, Ramiro Trillo, J. M. Vazquez, Peter den Heijer, Ton Slagboom, A.G. Vuillomenet 1

2. Potential conflicts of interest
Speaker’s name: Pieter C. Smits
 I have the following potential conflicts of interest to report:
 Research contracts: Boston Scientific, Abbott Vascular, Terumo  Consulting: Blue Medical
 Employment in industry; none
 Stockholder of a healthcare company; none
 Owner of a healthcare company; none
 Other(s): travel and speaking fees from Abbott Vascular 2

3. BACKGROUND COMPARE II trial Multivessel treatment
The role of percutaneous coronary intervention (PCI) in the treatment of multivessel coronary artery disease (CAD) is still controversial and widely discussed. More liberal use of drug-eluting stents (DES) increased proportion of those patients undergoing PCI procedure, raising a need for more clinical evidence.
The recent reported COMPARE II trial showed similar results of Biolimus-eluting Nobori stent (BES) and Everolimus-eluting Xience/Promus stent (EES) at 1-year in an all comers population.
We aim to compare safety and efficacy outcomes in patients with multivessel CAD (a pre-specified study subset) treated with BES and EES in COMPARE II trial.

4. Methodology COMPARE II trial Multivessel treatment 12 sites
Total Population: patients
Randomization 1：2
Non Inferiority Design
DAPT up to 12 months
12 sites
PI: Dr. P. Smits
EES
n = 912
BES
n = 1795
Patients with Multiple vessels treated
(> 1 major coronary artery and/or LM treatment)
EES (Multivessel)
n =230
BES (Multivessel)
n = 453
Clinical Follow-up 0d
30d
12mo
3yr
5yr
Primary endpoint at 12 months　: Composite of cardiac death, non-fatal myocardial Infarction and clinically indicated target vessel revascularization

5. Baseline Characteristics
COMPARE II trial Multivessel treatment
Baseline Characteristics
EES
230 pts
BES
453 pts
P-value
Age 64
0.4
Female, %
21.3
21.9
0.9
Previous cardiac history (%)
Previous AMI, %
17.4
22.0
0.2
Previous PTCA, %
14.4
15.7
0.7
Previous CABG, %
5.7
5.3
0.8
CV Risk Factors (%) DM
25.7
23.0
Hypertension
61.7
57.0
0.3
Current smoker
24.4
26.5
0.6

6. Clinical Presentation
COMPARE II trial Multivessel treatment
Clinical Presentation
EES
BES

7. Lesion Characteristics
COMPARE II trial Multivessel treatment
Lesion Characteristics
(%)
EES
(606 lesions)
BES
(1124 lesions) p
Ostial
14.0
15.2
0.5
Thrombotic
12.4
11.7
0.7
Bifurcation
6.3
6.4
1.0
Calcification (moderate/severe)
33.5
35.3
Chronic Total Occluded
2.5
3.1

8. Lesion Location COMPARE II trial Multivessel treatment EES
(606 lesions)
BES
(1124 lesions) p
LAD
35.3
36.4
0.3
RCA
31.0
33.4 Cx
31.5
27.4 LM
2.0
2.1
SVG
0.2
0.7 8

9. Procedural Characteristics
COMPARE II trial Multivessel treatment
Procedural Characteristics
EES
(606 lesions)
BES
(1124 lesions) p
Lesions treated per patient
2.57±0.90
2.48±0.77
0.2
Stent per lesion
1.43±0.75
1.47±0.81
0.4
Direct stenting (%)
41.9
36.0
0.01

10. Composite of Cardiac Death, MI, Clinically Indicated TVR
COMPARE II trial Multivessel treatment
Primary Endpoint
Composite of Cardiac Death, MI, Clinically Indicated TVR
P=NS

11. TLF: Composite of Cardiac Death, MI, Clinically Indicated TLR
COMPARE II trial Multivessel treatment
Secondary Endpoint
TLF: Composite of Cardiac Death, MI, Clinically Indicated TLR
P=NS

12. (Definite & Probable; ARC Definition)
COMPARE II trial Multivessel treatment
Stent Thrombosis (ARC)
(Definite & Probable; ARC Definition)

13. COMPARE II trial Multivessel treatment
Conclusions
Although this substudy was not powered to detect differences between the two stents, the BES with biodegradable polymer, was found as safe and effective as the EES even in this challenging patients population.
This study adds valuable evidence about clinical outcomes in patients with multivessel disease treated with contemporary DES.